They will need to demonstrate early traction with PCM and clinical data to feed the marketing engine. Originally, I'd thought we'd get the instant pass to $12.. Now-it looks like there could be some wait and see before the next act I.E $12?
Doug- question still comes down to this: How is Donovan going to make money with software licensing? He' needs a model that deliver residual stream of revenues (post site license).
Do you think PXLW revenues were related to Apple TV?. I'm not sure but- I think CEO squashed project? SO- are we looking at other devices with IRIS slot, to be launched from AAPL?
Simple- if you own the stock you must be committed to the stock, as there isn't a daily trade factor attached. I'm thinking of adding more shares and putting this thing back at $3.21. Your seeing normal profit-taking and Hors d'oeuvres market makers working over trading stock.
Most folks have been waiting for EMAN to cross the divide: both profit and development activities. While- profit isn't a shoe-in, evidence of break-even dollar figure is better defined. And completion of HMD could shed light on revenue potential vs speculative derived eps forecast. So- outside of PPS discount or non-parity to group- valuation, underlining events mentioned provide way for possible catalyst event/s. Stay tuned- rubber hasn't met the road yet.
Earnings showed cash preservation is possible (No cap raise in years is a good thing). And with product volume combined with leveraging of fixed cost, earnings are possible. HMD is a big thing if praise is received and name plate partner is identified. So with the earnings guess out of the way- its showtime. PPS will be in the $4-s or higher should ducks align?
Volume will resurface- low P/S ratio vs peers and possible game changing product within sector, still in search for the best in breed?